Evidence map›Paper›PMID 35891185›Full record

ArticleVaccines2022

Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report.

Federica Calò, Lorenzo Onorato, Mariantonietta Pisaturo, Antonio Pinto, Loredana Alessio, Caterina Monari, Carmine Minichini, Manuela Arcamone, Alessandra Di Fraia, Luigi Atripaldi and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Federica CalòDepartment of Mental Health and Public Medicine-Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
Lorenzo OnoratoDepartment of Mental Health and Public Medicine-Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
Mariantonietta PisaturoDepartment of Mental Health and Public Medicine-Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
Antonio PintoHematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, 80131 Naples, Italy.
Loredana AlessioDepartment of Mental Health and Public Medicine-Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
Caterina MonariDepartment of Mental Health and Public Medicine-Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
Carmine MinichiniDepartment of Mental Health and Public Medicine-Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
Manuela ArcamoneHematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, 80131 Naples, Italy.
Alessandra Di FraiaDepartment of Mental Health and Public Medicine-Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
Luigi AtripaldiU.O.C. di Patologia Clinica Ospedale D. Cotugno, Azienda Sanitaria Ospedali dei Colli, 80131 Naples, Italy.
Claudia TiberioU.O.C. di Patologia Clinica Ospedale D. Cotugno, Azienda Sanitaria Ospedali dei Colli, 80131 Naples, Italy.
Nicola CoppolaDepartment of Mental Health and Public Medicine-Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.ORCID 0000-0001-5897-4949
University of Campania "Luigi Vanvitelli" · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITOspedale D. Cotugno · IT

Funding

Regione Campania POR 2020
6 · The paper itself

Abstract

Few data are available regarding the effectiveness of anti-SARS-CoV-2 vaccine in immunocompromised patients. Vaccination may have a suboptimal efficacy in this population, in particular if patients are exposed to anti-B-cell therapy. We report the virological and clinical characteristics of a patient with follicle center lymphoma under bimonthly maintenance therapy with obinutuzumab, an anti-CD20 monoclonal antibody. Despite three doses of BNT162b2 vaccine, the patient was infected by the SARS-CoV-2 Omicron variant. After an initial period of clinical and molecular remission due to early therapy with sotrovimab, the patient experienced a fatal relapse sustained by the same viral strain.

Indexed as

anti-B cells monoclonal antibodiesCOVID-19mRNA vaccineoncohematological diseasesrelapseSARS-CoV-2

Identifiers

PMID35891185
PMCPMC9323164
OpenAlexW4283581624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.